At the European Cancer Congress (ECC) 2015, Georgina Long, BSc, PhD, MBBS, FRACP, of The University of Sydney, Sydney, Australia, discusses the safety data from the phase 1b part of MASTERKEY-265 , a phase 1b/3 clinical trial that was designed to evaluate the treatment of talimogene laherparepvec (T-VEC), a herpes simplex virus-1, and pembrolizumab, an anti-PD-1 antibody, for the treatment of patients with unresectable stage IIIB-IV melanoma.
MASTERKEY-265: Phase 1b/3 trial of T-VEC and pembrolizumab for unresectable stage IIIB-IV melanoma
9th December 2015
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.Join Now